Please login to the form below

Not currently logged in
Email:
Password:

Chris Molloy is new head of RSA

Life sciences executive search and interim management specialist RSA has appointed a new chief executive

RSA Chris MolloyChris Molloy, a non-executive director at RSA since 2009, joins RSA in a full-time capacity from IDBS, where he was VP, corporate development and marketing.

Molloy brings with him more than 20 years' experience in life sciences, spanning the pharmaceuticals, biotechnology and start-up sectors.

He started out with Glaxo, where he held a range of management, research, business change and scientific collaboration roles through the company's merger to become GlaxoSmithKline (GSK), before moving to Asia in 2004 as chief operating officer of emerging biotech firm MerLion Pharmaceuticals.

In addition to taking over as CEO at RSA, Molloy will retain his active scientific role in the pre-clinical development and licensing of new medicines for HIV with KFLP Biotech, a 'virtual' US R&D company.

“We are excited to have Chris on board as RSA's CEO. He will continue to preserve the special culture and feel of RSA whilst making us even more professional as an executive search and interim business,” said executive chairman Nick Stephens.

11th September 2013

From: Sales, Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics